Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3
作者：
Schmidt, Andrew [1 ]
Azad, Arun [2 ]
Goh, Jeffrey [3 ,4 ]
Harris, Carole [5 ,6 ]
Joshua, Anthony M. [7 ]
Weickhardt, Andrew [8 ]
Krieger, Laurence [9 ]
机构：
[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia
[4] Univ Queensland, St Lucia, Qld, Australia
[5] St George Hosp, Kogarah, NSW, Australia
[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia
[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;
D O I：
10.1111/ajco.13289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
引用
收藏
页码：3 / 10
页数：8
相关论文
共 50 条
  • [31] Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting
    de Velasco, Guillermo
    Hamieh, Lana
    Mickey, Suzanne
    Choueiri, Toni K.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 538 - 545
  • [32] New treatment options for metastatic renal cell carcinoma
    Rodriguez-Vida, Alejo
    Hutson, Thomas E.
    Bellmunt, Joaquim
    Strijbos, Michiel H.
    ESMO OPEN, 2017, 2 (02)
  • [33] Systemic therapy of metastatic renal cell carcinoma
    Maute, Luise
    Bergmann, Lothar
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (07) : 466 - 469
  • [34] First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
    Fontes-Sousa, Mario
    Calvo, Emiliano
    CANCER TREATMENT REVIEWS, 2022, 105
  • [35] First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options
    Loo, Vivian
    Salgia, Meghan
    Bergerot, Paulo
    Philip, Errol J.
    Pal, Sumanta K.
    TARGETED ONCOLOGY, 2019, 14 (06) : 639 - 645
  • [36] Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
    Carles, Joan
    Chirivella, Isabel
    Angel Climent, Miguel
    Gallardo, Enrique
    Gonzalez del Alba, Arancha
    Pablo Maroto, Jose
    Mellado, Begona
    Garcia del Muro, Francisco Xavier
    CANCER AND METASTASIS REVIEWS, 2012, 31 : S3 - S9
  • [37] Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
    Yaman, Samet
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2019, 15 (09) : 925 - 927
  • [38] First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Hahn, Andrew W.
    Klaassen, Zachary
    Agarwal, Neeraj
    Haaland, Benjamin
    Esther, John
    Ye, Xiang Y.
    Wang, Xuechen
    Pal, Sumanta K.
    Wallis, Christopher J. D.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 708 - 715
  • [39] Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy
    Schmidinger, Manuela
    Zielinski, Christoph C.
    CANCER TREATMENT REVIEWS, 2009, 35 (03) : 289 - 296
  • [40] First-line ICIs in renal cell carcinoma
    Fiorentino, Vincenzo
    Tralongo, Pietro
    Larocca, Luigi Maria
    Pizzimenti, Cristina
    Martini, Maurizio
    Pierconti, Francesco
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
12345